NASDAQ · BBIO
Healthcare · Biotechnology
$68.39
Down-$3.99 (-5.51%)
Updated Sep 16, 2026, 10:13 AM
SID Score
5.1/10
Composite research score
Smart Money
59/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BBIO closed at $68.39 after 20 trading sessions, down 17.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $72.26 | $72.405 | $66.955 | $68.39 | 3.99M |
| Sep 14, 2026 | $72.55 | $73.67 | $72.165 | $72.38 | 1.85M |
| Sep 11, 2026 | $73.225 | $74.105 | $71.98 | $72.44 | 1.77M |
| Sep 10, 2026 | $75.27 | $75.50 | $72.12 | $72.50 | 3.06M |
| Sep 9, 2026 | $73.63 | $76.81 | $73.465 | $76.08 | 2.31M |
| Sep 8, 2026 | $73.60 | $76.34 | $73.26 | $74.76 | 2.09M |
| Sep 4, 2026 | $74.98 | $75.365 | $74.11 | $74.84 | 1.54M |
| Sep 3, 2026 | $76.43 | $76.64 | $75.20 | $75.41 | 1.1M |
| Sep 2, 2026 | $76.60 | $78.2499 | $75.955 | $76.50 | 1.62M |
| Sep 1, 2026 | $76.61 | $77.451 | $76.22 | $76.57 | 1.45M |
| Aug 31, 2026 | $76.20 | $77.235 | $75.02 | $76.59 | 2.06M |
| Aug 28, 2026 | $79.99 | $80.55 | $76.34 | $76.60 | 1.92M |
| Aug 27, 2026 | $79.25 | $79.725 | $78.34 | $78.68 | 1.03M |
| Aug 26, 2026 | $79.75 | $80.76 | $79.33 | $79.37 | 1.71M |
| Aug 25, 2026 | $81.89 | $82.50 | $80.20 | $80.40 | 1.47M |
| Aug 24, 2026 | $80.98 | $81.68 | $80.16 | $81.07 | 1.11M |
| Aug 21, 2026 | $82.89 | $83.3667 | $81.36 | $81.50 | 1.74M |
| Aug 20, 2026 | $83.51 | $84.3646 | $82.63 | $82.94 | 2.03M |
| Aug 19, 2026 | $84.22 | $85.65 | $83.25 | $83.95 | 3.29M |
| Aug 18, 2026 | $80.54 | $83.95 | $80.10 | $82.98 | 2.72M |
The latest Smart Investors Daily articles mentioning BBIO.
BBIO research
Company profile and research snapshot.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 1, 2026 | Mizuho | Outperform | — |
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
BridgeBio Pharma, Inc. (BBIO) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:10 AM EDTCompany ParticipantsChinmay Shukla -...
SeekingAlpha · Sep 10, 2026
Benzinga · Sep 10, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
SeekingAlpha · Sep 9, 2026
BridgeBio Pharma, Inc. (BBIO) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 1:30 PM EDTCompany ParticipantsChinmay Shukla - Senior Vice...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BBIO.
